Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.

Abstract: Cancer vaccines were demonstrated to be promising strategies for cancer treatment; however these strategies are limited by the paucity of target antigens that provoke an effective immune response. The Inventors of the present patent application propose that sperm fibrous sheet proteins constitute a new class of potential antigens for use in the development of effective, durable cancer vaccines. This hypothesis is supported by the expression of the sperm fibrous sheath protein, known as Sperm protein 17 (Sp17), which is detected in tumors of unrelated histological origin. It has the ability to induce T-cell based immune responses. The expression of the Sperm protein 17 (Sp17) in tumors of unrelated histological origin, and its' natural localization in the human sperm fibrous sheath (FS), led the Inventors to hypothesize that FS proteins might represent a new potential class of target antigens useful for developing cancer vaccines, as well as diagnostic and therapeutic treatments.

Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.

Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. One such peptide, NMLSTVLGV (SEQ ID NO: 183) is useful to elicit an immune response against influenza. The present invention also provides a heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ ID NO: 183) and at least one different peptide.

Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.

Abstract: This disclosure provides a method for determining if a patient is likely to, or not likely to, experience ovarian cancer utilizing SP17 as a biomarker. It also provides methods and therapies to treat patients identified as at risk for ovarian cancer or alternatively, as identified as having a poorer prognosis.

Abstract: A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.

Abstract: This invention provides compositions and method for inhibiting and treating an HPV infection of LC or tissue containing LC by administering to the LC or tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV infection. It also provides methods to design antiviral and/or anticancer agents for cancers that harbor HPV.

Abstract: There is provided a method of activating a Langerhans cell (LC) exposed to a human papillomavirus (HPV) to induce a HPV-specific immune response, by administering to a subject an effective amount of a toll-like receptor (TLR) agonist, thereby activating the LC exposed to the HPV to induce the HPV-specific immune response.

Abstract: Cancer vaccines were demonstrated to be promising strategies for cancer treatment but the strategies are limited by the paucity of target antigens that provoke an effective immune response. We propose that sperm fibrous sheet proteins constitute a new class of potential antigens for cancer vaccines. This hypothesis is supported by the expression of the sperm fibrous sheath protein known as Sperm protein 17 detected in tumors of unrelated histological origin. It has the ability to induce T-cell based immune responses. The expression of the Sperm protein 17 (Sp17) in tumors of unrelated histological origin, and its natural localization in the human sperm fibrous sheath (FS), led us to hypothesize that FS proteins might represent a new potential class of target antigens useful for developing cancer vaccines and diagnostic and therapeutic treatments.

Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.

Abstract: A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.

Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.

Abstract: The present invention provides a chimeric protein including a first domain which includes at least a portion of a papillomavirus L1 or L2 protein and a second domain which includes a biotin-binding polypeptide. The invention also provides papillomaviruses, capsomeres, and VLPs including such chimeric proteins and a method for delivering biotinylated substances to cells using such reagents.

Abstract: The present invention provides methods and reagents for treating or preventing papillomavirus infection. In one aspect, the invention provides reagents and methods for attenuating the ability of papillomavirus to bind to cells by blocking access of papillomavirus to its cellular receptor. In another aspect, the invention provides reagents and methods for attenuating the ability of papillomavirus to infect cells by reducing the free titer of papillomavirus. In yet another aspect, the invention provides a complex comprising a biologically active substance and a ligand that recognizes CD16 and a method of delivering a biologically active substance to an papillomavirus-infected cell using the complex.

Abstract: The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.

Abstract: The invention relates to a rope for the taking along and transferring of paper webs in the manufacture on paper machines of paper and cardboard made from round-braided textile fiber material. In accordance with the invention, raised positions are distributed over the circumference of the rope at regular or irregular distances. The raised positions are generated by design measures such as the selection of a different multiple thread count in the different running directions and/or the use of twisted and laid fiber elements, and/or by the use of fibers with profiled fiber cross-sections and/or textured or crimped fiber yarns and or by the use of fibers with profiled fiber crosssections and/or textured or crimped fiber yarns.

Abstract: A peptide comprising an amino acid sequence derived from human p53 protein, wherein said amino acid sequence has the ability to bind to a human MHC Class I molecule. Its use in prophylactic or therapeutic treatment of diseases such as human cancers showing p53 protein overexpression, and its use in induction of primary p53-specific T cells that can be used in therapeutic treatment. Its use in diagnostic tests or assays.